Mangalam Drugs And Organics Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: MANGALAM BSE: 532637

₹30.74

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #152 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Mangalam Drugs And Organics Limited (this stock)	49	—	-35.9%	-57.0%	—	20	100	33

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹150 Cr

EV / EBITDA

Data unavailable.

EV / Sales

0.65x

Market cap / Sales

0.21x

Earnings yield

Data unavailable.

Quarterly Financials

Download CSV

Standalone Consolidated

↓ Negative

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 57 Cr, down 0.2% YoY.

↓ Negative

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs -8 Cr, down 45.0% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	57	-7	-8	₹-4.7700
March 31, 2026	67	-13	-13	₹-8.2500
Dec. 31, 2025	58	-10	-10	₹-6.1800
Sept. 30, 2025	50	-12	—	₹-4.5800
June 30, 2025	57	-13	-14	₹-8.6700
March 31, 2025	73	2	0	₹0.1000
Dec. 31, 2024	89	1	1	₹0.8900
Sept. 30, 2024	80	1	3	₹1.7000
June 30, 2024	77	1	3	₹1.7000
March 31, 2024	102	4	4	₹2.2400
Dec. 31, 2023	97	0	1	₹0.3200
Sept. 30, 2023	82	-5	-4	₹-2.2500
June 30, 2023	87	-10	-10	₹-6.0200

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	57	67	59	50	—	73	89	80	77	102	97	82	87
Operating revenue	57	67	58	50	57	73	89	80	77	102	97	82	87
Other income	0	0	0	0	—	-0	0	0	0	0	0	0	0
Operating expenses	56	73	60	52	62	63	80	71	68	91	90	79	91
Operating profit	1	-5	-1	-3	-5	11	9	9	8	12	7	2	-3
Operating profit margin	1.6%	-8.0%	-2.5%	-5.7%	-7.9%	14.4%	9.9%	10.9%	10.7%	11.4%	7.2%	2.7%	-4.0%
Depreciation	4	5	4	5	4	5	4	4	4	4	4	4	3
Interest	4	3	4	5	4	4	3	4	4	4	3	3	3
Exceptional items, gain / (loss)	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit before tax	-7	-13	-10	-12	-13	2	1	1	1	4	0	-5	-10
Tax	1	0	0	-5	1	2	0	-1	-2	0	-0	-1	-1
Net profit	-8	—	—	—	-14	0	1	3	3	4	0	-4	-10
EPS	-4.77	-8.25	-6.18	-4.58	-8.67	0.10	0.89	1.70	1.70	2.24	0.32	-2.25	-6.02
Net profit (TTM)	—	—	—	—	-9	7	10	9	3	-9	-17	-17	-11
EPS (TTM)	-23.78	-27.68	-19.33	-12.26	-5.98	4.39	6.53	5.96	2.01	-5.71	-10.72	-10.77	-7.11

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	232	-48	-44
March 31, 2025	318	5	7
March 31, 2024	369	-11	-9
March 31, 2023	372	2	1

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	—	—	—	318^†	369^†	373^†	—	385^†	284^†	228^†	285^†	312^†
Operating revenue	-14.6%	-9.4%	232	318	369	372	434^†	380^†	282^†	228^†	284^†	312^†
Other income	—	—	—	0^†	0^†	0^†	—	5^†	1^†	0^†	1^†	0^†
Operating expenses	—	—	247^†	282^†	351^†	347^†	402^†	327^†	259^†	—	—	256^†
Operating profit	—	—	-15^†	36^†	17^†	26^†	32^†	53^†	24^†	—	—	55^†
Operating profit margin	—	—	-6.3%^†	11.4%^†	4.7%^†	6.9%^†	7.3%^†	14.0%^†	8.4%^†	—	—	17.7%^†
Depreciation	—	—	18^†	16^†	15^†	11^†	10^†	9^†	8^†	—	—	5^†
Interest	—	—	16^†	15^†	14^†	13^†	11^†	9^†	10^†	9^†	12^†	10^†
Exceptional items, gain / (loss)	—	—	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	—	—	-48	5	-11	2	28^†	40^†	6^†	-6^†	29^†	33^†
Tax	—	—	-4^†	-2^†	-2^†	1^†	8^†	12^†	-2^†	2^†	9^†	10^†
Net profit	—	—	-44	7	-9	1	20^†	28^†	8^†	-8^†	20^†	24^†
EPS	—	—	-27.68^†	4.39^†	-5.71^†	0.83^†	12.42^†	17.67^†	5.21^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	-6.3%^†	11.4%^†	4.7%^†	6.9%^†	7.3%^†	14.0%^†	8.4%^†	—	—	17.7%^†
EBIT margin	-13.7%^†	6.3%^†	0.8%^†	4.0%^†	9.0%^†	12.8%^†	5.9%^†	1.3%^†	14.5%^†	13.9%^†
PBT margin	-20.7%	1.6%	-3.0%	0.6%	6.4%^†	10.4%^†	2.2%^†	-2.5%^†	10.3%^†	10.7%^†
Net margin	-18.9%	2.2%	-2.5%	0.3%	4.5%^†	7.4%^†	2.9%^†	-3.5%^†	7.0%^†	7.6%^†
Interest coverage	-1.96x^†	1.33x^†	0.21x^†	1.17x^†	3.48x^†	5.24x^†	1.60x^†	0.34x^†	3.49x^†	4.33x^†
Dividend payout	—	0.0%^†	—	0.0%^†	0.0%^†	0.0%^†	0.0%^†	—	—	—
Earnings retention	—	100.0%^†	—	100.0%^†	100.0%^†	100.0%^†	100.0%^†	—	—	—
Current ratio	0.82x	1.08x	—	—	—	—	—	—	—	—
Quick ratio	0.28x	0.33x	—	—	—	—	—	—	—	—
Debt to equity	0.99x	0.55x	—	—	—	—	—	—	—	—
Return on equity	-42.4%	4.7%	—	—	—	—	—	—	—	—
Return on assets	-14.2%	1.9%	—	—	—	—	—	—	—	—
Return on capital employed	-26.8%^†	11.4%^†	—	—	—	—	—	—	—	—
Asset turnover	0.75x	0.89x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	4	-12	6	12	-8
March 31, 2025	43	19	-22	-20	63
March 31, 2024	12	-18	6	18	-6
March 31, 2023	40	-22	-17	28	12
March 31, 2022	31	-27	-2	28	3

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	308	103	87	95	7	156	189	1	109	103
March 31, 2025	359	149	133	72	9	199	185	3	112	139
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.